Entrada Therapeutics, Inc. (TRDA) Tops Q1 EPS by 7c

Entrada Therapeutics, Inc. (NASDAQ: TRDA) reported Q1 EPS of ($0.95), $0.07 better than the analyst estimate of ($1.02). Revenue for the quarter came in at $875 thousand versus the consensus estimate of $3.34 million.

For earnings history and earnings-related data on Entrada Therapeutics, Inc. (TRDA) click here.

You May Also Be Interested In

• Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
• Citigroup set to join top banks in Anthropic IPO - Bloomberg
• Holcim to acquire Fermacell from James Hardie for EUR 840M